A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
Kagawa S, Muraoka A, Kambara T, Nakayama H, Hamano R, Tanaka N, Noma K, Tanakaya K, Kishimoto H, Shigeyasu K, Kuroda S, Kikuchi S, Kuwada K, Nishizaki M, Shirakawa Y, Fujiwara T.
Kagawa S, et al. Among authors: muraoka a.
Cancer Chemother Pharmacol. 2018 Feb;81(2):387-392. doi: 10.1007/s00280-017-3505-4. Epub 2017 Dec 30.
Cancer Chemother Pharmacol. 2018.
PMID: 29290024
Clinical Trial.